Thank you, Thomas. It is great to be here. And thank you all for dialing in to what is my very first Bactiguard quarterly report, delivered on my second Thursday as the CEO. As I stated in the CEO comments, I am looking forward to working with our sophisticated Board of Directors, including with Thomas as the incoming chairman as well as Kristen King in his new role as Senior Advisor. It is so valuable to have this full support. For those of you to whom I am new. My quick background. I have spent more than 25 years in and around the life sciences sector, including in CEO and business development and strategy positions, as well as in investment banking at Merrill Lynch in New York, advising biotech and pharma companies. I am an American, hence my very American accent. I have lived in Sweden since 2015 and yes, I do speak Swedish. Turning more importantly to the Q1 2024 report. The key message that we want to relay is that the strategic transformation has been concluded, and I would like to provide more details on that. If you have followed Bactiguard for a while, you will recognize this slide. We first showed it in connection with the announcement of the sharpened License Focus strategy in Q3, and I would like to go through it one last time to showcase what we have achieved in terms of the transformation and restructuring of the company. Let us review these achievements by the articulated focus area, starting with licensing. First, we have strengthened the organization both in terms of capabilities and ways of working. We are now working in a project-based manner, with the partner relationship in focus, with the aim to continue to strengthen long-term collaborations through teamwork and accountability for results so that Bactiguard is recognized as a true partner, rather than being seen solely as a solution provider or a contract manufacturer. Second, we have already enhanced the relationships with our current partners, in particular with BD (Becton, Dickinson and Company), but also with Zimmer Biomet. I will come back to this a little bit later in the presentation. Third, we are intensely engaged in dialogue with new potential partners. However, given the new way we will report revenues, we will not provide more information on these new partners until we enter exclusivity partnerships. In other words, we will announce once we are closer to starting to generate revenues, which we believe is more relevant from a financial perspective. Later in the presentation, Patrick will elaborate further on the framework for the reporting of our various partnership stages. The next focus area is R&D and our coating technology. We have further institutionalized the entire R&D organization, processes, and structure. We have kicked off the Billy Södervall Academy, although this is still in very early days, so I will not formally tick that off yet. Lastly, work is well underway on the production and laboratory facility in Madrid, and we hope to have it up and running sometime during Q2. Going forward, all coating, materials, production, and development activities will take place in Sweden in one of our two facilities in Tullinge or Märsta. Turning to the BIP portfolio. Importantly, we licensed out the full list to BD and the handover process of these additional markets is making great progress. We're in the final stages of winding down sales of our own medical devices for the CDSCO and ETS. We are in conversations with potential partners, but it is still too early to report on, and it is important to note that we expect these activities to have very limited impact in 2024. To summarize the financial impact of the strategic transformation, we are on track to deliver cost savings of more than 25 million SEK on a yearly basis. Separate from the licensing strategy. I would also like to emphasize our focus on growing the wound management business, consisting of both the wound healing offering of Hydrocyn aqua, and a wide range of surgical sutures, including specialist sutures for cardiovascular and ocular operations. In its totality, this sharpened strategy is how we will be able to deliver on our vision to be the premier partner to leading medtech companies, joining forces to redefine infection prevention and improve health worldwide. This is the last time we will address this slide. Q1 will be the last quarter characterized by the transformation, but we expect continued activities stemming from the transformation during the remainder of 2024 as we fully transition to the new strategy. So let's dig into our business. Becton, Dickinson, or BD, is one of the global market leaders within the urology therapeutic area. BD is our longest, strongest, and closest partnership. In fact, we have been partners with BD since 1995 and over the years, more than 230 million Bactiguard coated Foley catheters have been sold. No adverse events associated with the coating technology have been reported, and the product has generated more than 3.5 billion USD in additional sales for BD. With BD, we share common values and a commitment to always put patients first and have the ambition to make the world a healthier place. As mentioned already in the Q4 presentation, the estimated global market value of Foley catheters sold around the world is in excess of 1.5 billion USD annually, and is estimated to grow by around 5% every year. In the category of strengthening existing partnerships. BD is a perfect example. Late December last year, we signed an interim agreement granting BD an exclusive global license, excluding China, for Bactiguard coated Foley catheters, and an expanded long-term license agreement is expected to be signed during the first half of 2024. So what have we accomplished in Q1? Bactiguard obtained MDR regulatory approval in Europe for the coated silicone Foley catheters. This marks an important milestone as it will support and accelerate the go-to-market strategy in Europe. It is also a good example of Bactiguard's capabilities as a specialist and knowledge organization, where our ability to navigate the rather complex European regulatory landscape has provided great value to our partnership. We also attended BD's Global Sales and Marketing Summit in the US, where our BD project leader held a presentation on how our coating technology is differentiated and benefits their urology and critical care portfolios. This is really important to repeat, as the strength of our offering to our licensed partners is that the coating technology differentiates their medical devices in the market. So please keep that in mind. Some 50 BD sales and marketing leaders from various markets listened in and engaged in a lively Q&A. A little fun fact in the photo to the right is Micah Brinkley. This is BD's star salesman of Bactiguard coated catheters in the US. Clearly we have a lot of ambassadors within BD, and they are also a crucial part of the future potential for Bactiguard. In connection with the license agreement announced in December 2024 for additional markets for Bactiguard coated Foley catheters. The transition is ongoing and making great progress. The transfer will continue throughout 2024 and during this period, either we or BD will ensure that the market demand is met with the new agreement with BD. We believe our historically stable partnership is now strengthened and is a growing one. I'll start with a short recap of our partnership with Zimmer Biomet. Zimmer Biomet is a global leader in the orthopedic therapeutic area, and our partnership involves two categories. The first, signed in 2019, relates to Zimmer Biomet orthopedic trauma implants, for which Bactiguard received CE marking for the coated version in 2021. Today, this trauma nail system is called ZNN Bactiguard. In 2022, the partnership with Zimmer Biomet was expanded to cover multiple product segments, such as implants for various types of reconstructive surgeries. I would also like to mention that in 2023, Zimmer Biomet had an overarching strategic theme called Let's Talk About Infections, used at conferences and in various conversations. Bactiguard attended many of these, highlighting how our technology could prevent infections, a critical topic within orthopedic procedures. Looking at how the trauma collaboration specifically has developed in Q1, the demand for ZNN Bactiguard continues to increase following the launch across European markets in 2023. The uptake is, however, at a slower pace than we originally anticipated, but the interest and recognition among clinicians is strong, and the need for safe and effective infection prevention strategies is getting more and more attention. The next important event is the launch of ZNN Bactiguard in Japan, which is still planned at the end of Q2. Here again, we understand it will take some time before sales should be expected to ramp up. It is important to bear in mind that successful launch and sales of new technologies and products within our industry takes time and persistence. Together with Zimmer Biomet, we are continuously moving forward. Interestingly, once the ZNN Bactiguard is launched in Japan, Zimmer Biomet will offer Bactiguard coated products in markets representing around 50% of their trauma sales. We are confident that infection prevention is a very important issue to healthcare systems. Bactiguard coated products have strong clinical evidence and thus we know that our technology adds value. Coated products have strong clinical evidence and thus we know that our technology adds value. Now over to you, Patrick, to dig deeper into the financial results.